LabCorp to acquire clinical trials firm Chiltern for $1.2bn

02:01 EDT 1 Aug 2017 | Pharmaceutical Business Review

LabCorp has agreed to acquire specialty contract research organization (CRO) Chiltern for nearly $1.2bn in an all-cash deal to expand its oncology offerings.

Original Article: LabCorp to acquire clinical trials firm Chiltern for $1.2bn


More From BioPortfolio on "LabCorp to acquire clinical trials firm Chiltern for $1.2bn"

Quick Search

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...